External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Neuroscience CTAD 2026
Roche and Genentech at

CTAD 2026

November 16 - November 19
Boston, USA / Virtual (Hybrid)
ctad-alzheimer.com
We will be contributing to topics related to
Neuroscience
Add to calendar
Share feedback
Share page
-
Agenda
Medical Materials
07:00 PM
Duration 60mins Boston, USA
Rationale and design of TARBELA-AD: A Phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease
Loes Rutten-Jacobs, Venissa Machado, Paul Edison, Catherine Mummery, Alessandro Padovani, Malú Gámez Tansey, Silke Simon,Celine Adessi, Nikhat Parkar, Nima Shariati, Bastian Zinnhardt, Gabriel Schnetzler, Geoffrey A. Kerchner, Luka Kulic, Gennaro Pagano
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Boston, USA
Sex Matters in Alzheimer’s Disease: Gaps and Recommendations for Clinical Trials
Gillian Coughlan, Jill M. Goldstein, Roberta Diaz Brinton, Kristine Yaffe, Emily G. Jacobs, Roberta Marongiu, Kathryn Godburn Schubert, Heather Snyder, Jessica Z. K. Caldwell, Anna Chodos, Michelle Mielke, Lindsay R. Chura, Diana Slowiejko, Rachel Buckley
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:25 PM
Duration 20mins Boston, USA
A glimpse of the future: How diagnostics, therapies, trials, and concepts of prevention must evolve
Geoffrey A. Kerchner
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:50 PM
Duration 40mins Boston, USA
Advanced imaging results from the Brainshuttle™ AD study with trontinemab in Alzheimer’s disease
Gregory Klein, Gil D. Rabinovici, Henrik Zetterberg, Matteo Tonietto, Erica Silvestri, Anton Belousov, Fabien Alcaraz, Carsten Hofmann, João A. Abrantes, Orwa Albitar, Denise Sickert, Jakub Wojtowicz, Moreen Gabriel, Silke Ahlers, Paul Delmar, Janice Smith, Hanno Svoboda, Luka Kulic
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 40mins Boston, USA
Trontinemab in Alzheimer’s Disease- Novel Pharmacodynamic insights from the ongoing phase IB/IIA Brainshuttle™ AD study
Luka Kulic, Carsten Hofmann, João A. Abrantes, Fabien Alcaraz1 Gregory Klein, Denise Sickert, Jakub Wojtowicz, Moreen Gabriel, Silke Ahlers, Paul Delmar, Janice Smith, Hanno Svoboda
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:35 PM
Duration 40mins Boston, USA
The NLRP3 inflammasome as a therapeutic target in Alzheimer’s disease: biomarker, preclinical evidence and Phase I healthy participants’ safety data of the oral inhibitor RG6434
Gennaro Pagano
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:15 PM
Duration 60mins Boston, USA
Diagnostic accuracy of Elecsys pTau181 and pTau217 plasma assays using global cutoffs in an Asian cohort: Results from the K-ROAD registry
Annunziata di Domenico, Christian Kuffer, Gwendlyn Kollmorgen, Henrik Zetterberg, Jun Pyo Kim, Myrto Andreadou, Sang Won Seo, Sayuri Hortsch, Tobias Bittner
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Boston, USA
Elecsys pTau217 plasma assay cutoff determination and validation for the detection of amyloid pathology in a Chinese population
Chuantao Zuo, Guoyu Lan, Jiawei Xin, Jingtan Yu, Jun Hu, Mengjie Dong, Ming Guan, Qiman Yin, Tengfe Guo, Xiaochun Chen, Xuhui Chen, Yim Yung, Yingping Cao, Yuyuan Huang, Zhongyou Ji
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Boston, USA
Validation of Elecsys pTau217 plasma assay cutoffs for detection of amyloid pathology across care settings
Annunziata di Domenico, Christopher Rowe, Craig Ritchie, David Caley, Kaj Blennow, Marc Suarez Calvet, Marisa Denkinger, Ming Lu, Nicholas Ashton, Niels Borlinghaus, Oskar Hansson, Sameera Wijayawardana, Sayuri Hortsch, Sebastian Palmqvist
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Boston, USA
Diagnostic accuracy of the automated Elecsys CSF Aβ42/Aβ40 ratio and Aβ42 in a population reflective of real-world clinical practice
Cornelia Fütterer, David Caley, David Watson, Kristian Steen Frederiksen, MERCE BOADA ROVIRA, Marc Suarez Calvet, Myrto Andreadou
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Boston, USA
Re-evaluating TDP-43 assays: Hemolysis interference limits clinical utility
Anna Bayfield, Darina Laura Graziella Effert, Myrto Andreadou, Nicholas Ashton, Sterling Johnson
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Boston, USA
Mitigating amyloid endpoint heterogeneity to establish robust cutoffs and clinical performance of Elecsys pTau217 and pTau181 plasma immunoassays
Annunziata di Domenico, Christopher Rowe, Gregory Klein, Imke Kirste, James Doecke, Michael Weiner, Myrto Andreadou, Niklas Mattsson-Carlgren, Sayuri Hortsch, Sebastian Palmqvist, Tobias Bittner
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:55 PM
Duration 30mins Boston, USA
PrevenTRON: Evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer’s disease at high risk of clinical decline
Reisa Sperling, Catherine Mummery, Jeffrey L. Cummings, Gil Rabinovici, Stephen Salloway, Henrik Zetterberg, Juan Fortea, Frank G. Boess, Christopher Lane, Marion Monchalin, Paul Delmar, Luka Kulic, Hanno Svoboda, Geoffrey A. Kerchner, Janice Smith
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:15 PM
Duration 60mins Boston, USA
REACHED: Participant characteristics from a pilot pre-screening study designed to diversify clinical trial recruitment in understudied populations in Alzheimer’s disease
Alexandria Wise-Brown, Alison Buick, Frank Boess, Frank Perilli, Ira Goodman, Janice Smith, Karra Harrington, Kelly Coultes, Nicklas Linz, Nicola Antonio Maiorano, Ruth Croney
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 60mins Boston, USA
Clinical and Operational Determinants of Amyloid-Targeting Therapy Initiation in Early Alzheimer's Disease: A Discrete Choice Experiment
Elena García-Arcelay, Juan Fortea, Alberto Villarejo, Raquel Sánchez-Valle, Neus Canal, Mónica Sarmiento, Jorge Mauriño, Guillermo García-Ribas, Gustavo Saposnik
Neuroscience | Alzheimer Disease

You have successfully signed up for this alert. You will be notified when it is available.

Notify me

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Coming soon

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.